WO2024254480A3 - Formes à l'état solide de rencofilstat - Google Patents

Formes à l'état solide de rencofilstat Download PDF

Info

Publication number
WO2024254480A3
WO2024254480A3 PCT/US2024/033050 US2024033050W WO2024254480A3 WO 2024254480 A3 WO2024254480 A3 WO 2024254480A3 US 2024033050 W US2024033050 W US 2024033050W WO 2024254480 A3 WO2024254480 A3 WO 2024254480A3
Authority
WO
WIPO (PCT)
Prior art keywords
rencofilstat
solid state
state forms
same
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033050
Other languages
English (en)
Other versions
WO2024254480A2 (fr
Inventor
Robert Thomas FOSTER
Daniel Joseph TREPANIER
Thomas Paul ZABAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hepion Pharmaceuticals Inc
Original Assignee
Hepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepion Pharmaceuticals Inc filed Critical Hepion Pharmaceuticals Inc
Priority to EP24820149.3A priority Critical patent/EP4724081A2/fr
Priority to JP2025571429A priority patent/JP2026519628A/ja
Priority to AU2024285817A priority patent/AU2024285817A1/en
Priority to CN202480042275.3A priority patent/CN122206453A/zh
Publication of WO2024254480A2 publication Critical patent/WO2024254480A2/fr
Publication of WO2024254480A3 publication Critical patent/WO2024254480A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes à l'état solide de rencofilstat (RCF), des compositions pharmaceutiques les comprenant, ainsi que des méthodes de fabrication de formes posologiques pharmaceutiques les utilisant.
PCT/US2024/033050 2023-06-08 2024-06-07 Formes à l'état solide de rencofilstat Ceased WO2024254480A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP24820149.3A EP4724081A2 (fr) 2023-06-08 2024-06-07 Formes à l'état solide de rencofilstat
JP2025571429A JP2026519628A (ja) 2023-06-08 2024-06-07 レンコフィルスタットの固体状態の形態
AU2024285817A AU2024285817A1 (en) 2023-06-08 2024-06-07 Solid state forms of rencofilstat
CN202480042275.3A CN122206453A (zh) 2023-06-08 2024-06-07 伦可司他的固态形式

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471879P 2023-06-08 2023-06-08
US63/471,879 2023-06-08

Publications (2)

Publication Number Publication Date
WO2024254480A2 WO2024254480A2 (fr) 2024-12-12
WO2024254480A3 true WO2024254480A3 (fr) 2025-01-16

Family

ID=93794711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033050 Ceased WO2024254480A2 (fr) 2023-06-08 2024-06-07 Formes à l'état solide de rencofilstat

Country Status (5)

Country Link
EP (1) EP4724081A2 (fr)
JP (1) JP2026519628A (fr)
CN (1) CN122206453A (fr)
AU (1) AU2024285817A1 (fr)
WO (1) WO2024254480A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065433A1 (en) * 2010-10-12 2015-03-05 Allergan, Inc. Cyclosporin analogs
US20160207961A1 (en) * 2010-12-15 2016-07-21 Ciclofilin Pharmaceuticals Corp. Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
US20220168385A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065433A1 (en) * 2010-10-12 2015-03-05 Allergan, Inc. Cyclosporin analogs
US20160207961A1 (en) * 2010-12-15 2016-07-21 Ciclofilin Pharmaceuticals Corp. Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
US20220168385A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARRISON STEPHEN A., MAYO PATRICK R., HOBBS TODD M., CANIZARES CARLOS, FOSTER ERIN P., ZHAO CAROLINE, URE DAREN R., TREPANIER DANI: "Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH", HEPATOLOGY COMMUNICATIONS, vol. 6, no. 12, 1 December 2022 (2022-12-01), pages 3379 - 3392, XP093266737, ISSN: 2471-254X, DOI: 10.1002/hep4.2100 *

Also Published As

Publication number Publication date
JP2026519628A (ja) 2026-06-16
AU2024285817A1 (en) 2026-01-08
CN122206453A (zh) 2026-06-12
EP4724081A2 (fr) 2026-04-15
WO2024254480A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
EP4512399A3 (fr) Formes à l'état solide de tafamidis et leurs sels
WO2020083971A3 (fr) Nouveaux composés anthelminthiques
EP4360651A3 (fr) Compositions glp-1 et leurs utilisations
EP4674481A3 (fr) Inhibiteurs de cd73
AR033711A1 (es) Composiciones farmaceuticas
WO2022106902A8 (fr) Dérivés de benzènesulfonamide et leurs utilisations
EP4400098A3 (fr) Formes co-amorphes de beta-lactoglobuline et d'une substance medicamenteuse
MXPA03011546A (es) Formulacion farmaceutica.
HK1041816A1 (zh) 药片
AU2022215028A9 (en) Solid pharmaceutical compositions and methods of producing the same
WO2005097076A3 (fr) Produits pharmaceutiques a faibles doses
WO2002094856A3 (fr) Peptidomimetiques et analogues de gpe
WO2022207944A3 (fr) Nouveaux mélanges et utilisations de (2e)-3-(1,3-benzodioxol-5-yl)-n-phényl-n- (tétrahydro-3-furanyl)-2-propénamide
WO2024023585A3 (fr) Dérivés d'urolithine et utilisations thérapeutiques associées
WO2025057086A3 (fr) Compositions pharmaceutiques d'anticorps ciblant fcrn
WO2024163530A3 (fr) Nouveaux anticorps anti-ccr4 et produits dérivés
WO2007087026A3 (fr) Forme solide de amg 706 et compositions pharmaceutiques contenant ledit composé
WO2024259092A3 (fr) Anellovecteurs pour l'administration d'effecteurs dans le système nerveux central
WO2024015559A3 (fr) Formes solides de mésembrine et leurs utilisations thérapeutiques
AU2023473631A1 (en) Solid state forms, pharmaceutical compositions, preparation methods and use thereof
WO2025094081A3 (fr) Formes à l'état solide de deutivacaftor et procédé associé
WO2023168249A3 (fr) Cystéamides, compositions thérapeutiques associées et procédés associés
WO2022040111A3 (fr) Formes à l'état solide de sels de l'erdafitinib et procédés de préparation de l'erdafitinib
WO2020086650A3 (fr) Nouveaux composés
WO2024173800A3 (fr) Formes solides de mésembranol et leurs utilisations thérapeutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024285817

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025571429

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024285817

Country of ref document: AU

Date of ref document: 20240607

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024820149

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820149

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

WWP Wipo information: published in national office

Ref document number: 2024820149

Country of ref document: EP